Expression of CD133 and Aldehyde Dehydrogenase 1A1 in Borderline Ovarian Tumor and Their Correlation with International Federation of Gynecology and Obstetrics
DOI:
https://doi.org/10.3889/oamjms.2020.3417Keywords:
Borderline ovarian tumor, International Federation of Gynecology and Obstetrics stage, CD133,, Aldehyde Dehydrogenase 1A1Abstract
BACKGROUND: Borderline ovarian tumor (BOT) is an epithelial ovarian tumor with atypical epithelial proliferation without stromal invasion. BOTs may have an aggressive fashion with associated microinvasion feature, peritoneal “implants,” regional lymphadenopathy, and higher International Federation of Gynecology and Obstetrics (FIGO) stage. CD133 is cancer stem cells (CSCs) marker that promotes cell proliferation and tumor invasion through induction of nuclear factor kappa B and upregulation of MMP9. Aldehyde dehydrogenase 1A1 (ALDH1A1) is CSCs marker that promotes cell proliferation through the upregulation of c-MYC and cyclin-D1.
AIM: The aim of this study was to investigate the correlation between CD133 and ALDH1A1 expression with FIGO stage. This research was performed as an analytic-observational with a cross-sectional design.
METHODS: This research using a paraffin block of patients diagnosed as BOT in Hasan Sadikin Hospital Bandung. Samples were divided in two groups: FIGO stage IA and FIGO stage >IA. All samples were stained by immunohistochemistry CD133 and ALDH1A1. All data were analyzed using the Chi-square test with a significant level 5%.
RESULTS: This study showed a statistically significant correlation between CD133 (p = 0.047) and ALDH1A1 (p = 0.042) expression with FIGO stage in BOT. Multivariate analysis showed there was no correlation between CD133 and ALDH1A1 in the affected of FIGO stage in BOT.
CONCLUSION: CD133 and ALDH1A1 in BOT can be considered as a factor to predict the prognosis of BOT through predict FIGO stage.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014. p. 15-39.
Patrono MG, Minig L, Diaz-Padilla I, Romero N, Moreno JF, Garcia-Donas J. Borderline tumours of the ovary, current controversies regarding their diagnosis and treatment. Ecancermedicalscience. 2013;7:379. PMid:24386008
Loizzi V, Selvaggi L, Leone L, Latorre D, Scrdigno D, Magazzino F, et al. Borderline epithelial tumors of the ovary: Experience of 55 patients. Oncol Lett. 2015;9(2):912-4. https:// doi.org/10.3892/ol.2014.2758 PMid:25621067
Lalwani N, Shanbhogue AK, Vikram R, Nagar A, Jagirdar J, Prasad SR. Current update on borderline ovarian neoplasms. AJR. 2010;194(2):330-6. https://doi.org/10.2214/ajr.09.3936 PMid:20093592
Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S, et al. CD133 antigen expression in ovarian cancer. BMC Cancer. 2009;9:221. https://doi.org/10.1186/1471-2407-9-221 PMid:19583859
Tao Y, Li H, Huang R, Mo D, Zeng T, Fang M, et al. Clinicopathological and prognostc significance of cancer stem cell markers in ovarian cancer patients: Evidence from 52 studies. Cell Physiol Biochem. 2018;46(6):1716-26. https://doi.org/10.1159/000489586 PMid:29730663
Li Z. CD133: A stem cell biomarker and beyond. Exp Hematol Oncol. 2013;2(1):17. PMid:23815814
Tomita H, Tanaka K, Tanaka T, Hara A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget. 2016;7(10):11018-27. https://doi.org/10.18632/oncotarget.6920 PMid:26783961
Javadi S, Ganeshan D, Qayyum A, Iyer R, Bhosale P. Ovarian cancer, the revised FIGO staging system, and the role of imaging. AJR Am J Roentgenol. 2016;206(6):1351-60. https:// doi.org/10.2214/ajr.15.15199 PMid:27042752
Suh DH, Kim TH, Kim JW, Kim SY, Kim HS, Lee TS, et al. Improvements to the FIGO staging for ovarian cancer: Reconsideration of lymphatic spread and intraoperative tumor rupture. J Gynecol Oncol. 2013;24(4):352-358. https://doi. org/10.3802/jgo.2013.24.4.352 PMid:24167671
Long H, Xiang T, Qi W, Huang J, Chen J, He L, et al. CD133+ ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition. Oncotarget. 2015;6(8):5846-59. https://doi.org/10.18632/ oncotarget.3462 PMid:25788271
Downloads
Published
How to Cite
License
Copyright (c) 2020 Birgitta M. Dewayani, Hasrayati Agustina, Desi Puspita, Bethy S. Hernowo, Sri Suryanti (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
